Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2019

22.07.2019 | Breast Oncology

Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations?

verfasst von: Constanze Elfgen, MD, Seraina Margaretha Schmid, MD, Christoph Johannes Tausch, MD, Giacomo Montagna, MD, Uwe Güth, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer patients with local and/or locoregional recurrence (LR) are at higher risk of developing distant metastases (DM) at a later time. Once LR has been confirmed, some international interdisciplinary guidelines recommend performing radiological examinations for DM to determine the course of further therapy (curative or palliative approach). This study analyzed the metastatic patterns of patients with LR with particular regard to the frequency of concurrent diagnosis of LR and DM; in other words: are radiological staging procedures actually justified for DM at the time of diagnosis of LR?

Methods

This study included all patients (n = 1368) who were diagnosed and treated for nonmetastatic breast cancer (Stage I–III) at the University Women’s Hospital Basel, Switzerland between 1990 and 2009.

Results

In 137 patients, LR was diagnosed without a history of DM: in-breast/thoracic wall only, n = 90 (65.7%); involvement of axillary/supra-/infraclavicular lymph nodes, n = 47 (34.3%). DM was found at the time of diagnosis of LR in 44 patients (32.1%). Concurrent diagnosis of LR and DM occurred significantly more often in patients with lymph node recurrence compared with those with in-breast/chest wall recurrence (48.9% vs. 23.3%; p = 0.004).

Conclusions

Approximately one-third of patients with a LR had synchronous DM at the time of their local/locoregional event. For this reason, routine systemic staging imaging at the time of LR should be an absolute requirement for planning further therapy. Confirmation of DM may spare the patients radical surgical interventions with questionable impact on survival in the face of an incurable disease.
Literatur
1.
Zurück zum Zitat van Laar C, van der Sangen MJ, Poortmans PM, et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer. 2013;49:3093–101.CrossRefPubMed van Laar C, van der Sangen MJ, Poortmans PM, et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer. 2013;49:3093–101.CrossRefPubMed
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef
3.
Zurück zum Zitat Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol. 2000;18:1696–709.CrossRefPubMed Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol. 2000;18:1696–709.CrossRefPubMed
4.
Zurück zum Zitat Buchanan CL, Dorn PL, Fey J, et al. Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg. 2006;203:469–74.CrossRefPubMed Buchanan CL, Dorn PL, Fey J, et al. Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg. 2006;203:469–74.CrossRefPubMed
5.
Zurück zum Zitat Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028–37.CrossRefPubMed Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028–37.CrossRefPubMed
6.
Zurück zum Zitat Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentral Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Senkus E, Kyriakides S, Ohno S, ESMO Guidelines Committee, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):8–30.CrossRef Senkus E, Kyriakides S, Ohno S, ESMO Guidelines Committee, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):8–30.CrossRef
10.
Zurück zum Zitat Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29:1634–57.CrossRefPubMed Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29:1634–57.CrossRefPubMed
12.
Zurück zum Zitat Haffty BG, Fischer D, Beinfield M, et al. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21:293–8.CrossRefPubMed Haffty BG, Fischer D, Beinfield M, et al. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21:293–8.CrossRefPubMed
13.
Zurück zum Zitat Harris EE, Hwang WT, Seyednejad F, et al. Prognosis after regional lymph node recurrence in patients with stage I–II breast carcinoma treated with breast conservation therapy. Cancer. 2003;98:2144–51.CrossRefPubMed Harris EE, Hwang WT, Seyednejad F, et al. Prognosis after regional lymph node recurrence in patients with stage I–II breast carcinoma treated with breast conservation therapy. Cancer. 2003;98:2144–51.CrossRefPubMed
14.
Zurück zum Zitat Tennant S, Evans A, Macmillan D, et al. CT staging of loco-regional breast cancer recurrence. A worthwhile practice? Clin Radiol. 2009;64:885–90.CrossRefPubMed Tennant S, Evans A, Macmillan D, et al. CT staging of loco-regional breast cancer recurrence. A worthwhile practice? Clin Radiol. 2009;64:885–90.CrossRefPubMed
15.
Zurück zum Zitat Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1999;43:25–38.CrossRefPubMed Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after breast conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 1999;43:25–38.CrossRefPubMed
16.
Zurück zum Zitat Van Oost FJ, van der Hoeven JJ, Hoekstra OS, et al. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer. 2004;40:1545–53.CrossRefPubMed Van Oost FJ, van der Hoeven JJ, Hoekstra OS, et al. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer. 2004;40:1545–53.CrossRefPubMed
17.
Zurück zum Zitat Yi M, Kronowitz SJ, Meric-Bernstam F, et al. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011;117:916–24.CrossRefPubMed Yi M, Kronowitz SJ, Meric-Bernstam F, et al. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011;117:916–24.CrossRefPubMed
18.
Zurück zum Zitat Neuman HB, Schumacher JR, Francescatti AB, The Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Group, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage II and III breast cancer (AFT-01). J Clin Oncol. 2018;36:975–80.CrossRefPubMedPubMedCentral Neuman HB, Schumacher JR, Francescatti AB, The Alliance/American College of Surgeons Clinical Research Program Cancer Care Delivery Research Breast Cancer Surveillance Working Group, et al. Risk of synchronous distant recurrence at time of locoregional recurrence in patients with stage II and III breast cancer (AFT-01). J Clin Oncol. 2018;36:975–80.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Amann E, Huang DJ, Weber WP, et al. Disease-related surgery in patients with distant metastatic breast cancer. Eur J Surg Oncol. 2013;39:1192–8.CrossRefPubMed Amann E, Huang DJ, Weber WP, et al. Disease-related surgery in patients with distant metastatic breast cancer. Eur J Surg Oncol. 2013;39:1192–8.CrossRefPubMed
20.
Zurück zum Zitat Güth U, Vetter M, Huang DJ, et al. Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendations for staging imaging of node negative, hormonal receptor negative disease. Ann Oncol. 2013;24:555–7.CrossRefPubMed Güth U, Vetter M, Huang DJ, et al. Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendations for staging imaging of node negative, hormonal receptor negative disease. Ann Oncol. 2013;24:555–7.CrossRefPubMed
21.
Zurück zum Zitat Wadasadawala T, Vadgaonkar R, Bajpai J. Management of isolated locoregional recurrences in breast cancer: a review of local and systemic modalities. Clin Breast Cancer. 2017;17:493–502.CrossRefPubMed Wadasadawala T, Vadgaonkar R, Bajpai J. Management of isolated locoregional recurrences in breast cancer: a review of local and systemic modalities. Clin Breast Cancer. 2017;17:493–502.CrossRefPubMed
22.
Zurück zum Zitat Chand AR, Ziauddin MF, Tang SC. Can locoregionally recurrent breast cancer be cured? Clin Breast Cancer. 2017;17:326–35.CrossRefPubMed Chand AR, Ziauddin MF, Tang SC. Can locoregionally recurrent breast cancer be cured? Clin Breast Cancer. 2017;17:326–35.CrossRefPubMed
23.
Zurück zum Zitat Xiao W, Zou Y, Zheng S, et al. Primary tumor resection in stage IV breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504–12.CrossRefPubMed Xiao W, Zou Y, Zheng S, et al. Primary tumor resection in stage IV breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2018;44:1504–12.CrossRefPubMed
24.
Zurück zum Zitat Khan SA, DesJardin ESM. Readdressing the role of surgery of the primary tumor in de novo stage IV breast cancer. Cancer Treat Res. 2018;173:73–88.CrossRefPubMed Khan SA, DesJardin ESM. Readdressing the role of surgery of the primary tumor in de novo stage IV breast cancer. Cancer Treat Res. 2018;173:73–88.CrossRefPubMed
Metadaten
Titel
Radiological Staging for Distant Metastases in Breast Cancer Patients with Confirmed Local and/or Locoregional Recurrence: How Useful are Current Guideline Recommendations?
verfasst von
Constanze Elfgen, MD
Seraina Margaretha Schmid, MD
Christoph Johannes Tausch, MD
Giacomo Montagna, MD
Uwe Güth, MD
Publikationsdatum
22.07.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07629-9

Weitere Artikel der Ausgabe 11/2019

Annals of Surgical Oncology 11/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.